Streetbeat News

Price Targets

PRLD

Morgan Stanley analyst Jeffrey Hung has downgraded Prelude Therapeutics (NASDAQ:PRLD) from Equal-Weight to Underweight and reduced the price target from $10 to $4. This reflects a more bearish outlook on the company's stock by the analyst.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:33 pm

VIGL

Morgan Stanley analyst Jeffrey Hung has downgraded Vigil Neuroscience (NASDAQ:VIGL) from Equal-Weight to Underweight and reduced the price target from $13 to $4.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:31 pm

IRON

Morgan Stanley analyst Jeffrey Hung has downgraded Disc Medicine (NASDAQ: IRON) from Overweight to Equal-Weight while increasing the price target from $56 to $65.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:29 pm

SCSC

Northcoast Research analyst Keith Housum has downgraded ScanSource (NASDAQ:SCSC) from Buy to Neutral and set a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:25 pm

CYCC

Roth MKM analyst Jonathan Aschoff has reaffirmed a Buy rating on Cyclacel Pharmaceuticals (NASDAQ:CYCC) and increased the price target from $16 to $21.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:25 pm

KYMR

Wells Fargo analyst Derek Archila has downgraded Kymera Therapeutics (KYMR) from Overweight to Equal-Weight and set a price target of $26.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:23 pm

MBI

Roth MKM analyst Harry Fong has maintained a Neutral rating on MBIA Inc. (NYSE:MBI) and has lowered the price target from $15 to $7.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:21 pm

FC

Roth MKM analyst Jeff Martin has maintained a Buy rating on Franklin Covey (NYSE:FC) but has reduced the price target from $61 to $59.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:17 pm

CMMB

Roth MKM analyst Dylan Dupuis has reinstated a Buy rating on Chemomab Therapeutics (NASDAQ:CMMB) with a maintained price target of $7.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:14 pm

RYTM

Morgan Stanley analyst Jeffrey Hung upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) from Equal-Weight to Overweight and increased the price target from $29 to $55.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:12 pm